No quarterly revenue total was found in AGENTIX CORP.'s SEC filings.
Agentix Corp. (AGTX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
$-117,674
+36.7% vs year-ago quarter
Operating cash flow
$-26,372
+77.7% vs year-ago quarter
Free cash flow
—
EPS
$0.00
Dividend per share
None
Shares outstanding
40.07M
+0.0% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AGTX (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- NV
- Headquarters
- Dana Point, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1603345
- Former names
- FairWind Energy Inc. (until Jun 27, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Jun 30, 2026 |
Q4 FY2026 Mar 31, 2026 |
Q3 FY2026 Dec 31, 2025 |
Q2 FY2026 Sep 30, 2025 |
Q1 FY2026 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$95,504 | -$54,285 | -$67,463 | -$123,097 | -$200,342 |
| Net income | -$117,674 | -$77,110 | -$78,595 | -$144,107 | -$185,824 |
| Diluted EPS | $0.00 | -$0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | -$26,372 | $14,776 | -$7,938 | $3,004 | -$118,371 |
| Total assets | $38 | $771 | $6,396 | $5,601 | $4,412 |
| Total liabilities | $3.7M | $3.6M | $3.5M | $3.4M | $3.3M |
| Stockholders' equity | -$3.7M | -$3.6M | -$3.5M | -$3.4M | -$3.3M |
| Cash and investments | $38 | $771 | $6,396 | $5,601 | $4,412 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 10-K | Annual report | Jul 1, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Feb 17, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 20, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 22, 2025 | Jun 30, 2025 |
| 10-K | Annual report | Jul 16, 2025 | Mar 31, 2025 |
All 153 Agentix Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.